Vice President, In Vivo Services
Director Cell Line Development and Upstream Process Development
Dr. Beske has greater than 25 years of cell biology and product development research experience. He has a Ph.D. in cell biology from the University of California, San Francisco. Following a stint as a professor at San Francisco State University he joined Vitra Bioscience and led a team of scientists developing novel cell based assay technologies with applications in drug discovery and basic science research. Subsequently, he founded Rilato Bioscience (recently acquired) and COREX Scientific where he continues to serve in an advisory role. Dr. Beske has multiple patents and publications pertaining to cell biology, multiplexed assays, and small molecule drug discovery. Dr. Beske joined Aragen Bioscience in 2007 and is currently the President of the company.
Dr. Ghosh has extensive expertise in molecular and cell biology studies ranging from discovery of novel disease related genes, gene expression profiling, functional studies on therapeutic targets to translation studies on animal models. Prior to joining Aragen, she was a staff scientist at Celliance Corporation where she worked on autoimmune disease models and in vivo oncology models. Dr. Ghosh has several years of experience in the biotech industry including diaDexus, Inc. where she led the Gene Discovery Group in colon cancer in work which resulted in several patents in the field of oncology. Dr. Ghosh received her Ph.D. in Molecular Biology from the University of Wyoming. Her postdoctoral research was in the field of hormone responsive breast cancer in the Department of Surgery at Stanford University where she was awarded several grants and was selected as a New Investigator by the Department of Defense Breast Cancer Research Program.
Mr. Rodewald brings 20+ years of Sales and Marketing Management to the Aragen team, including CRO Sales, CRISP /Cas9 licensing, biotechnology hardware/reagent platforms, and fully-integrated analytical systems. Prior to joining Aragen, Mr. Rodewald most recently worked with Horizon Discovery on the West Coast; prior to that he managed the APAC Cell-Based Imaging business for IntelliCyt and PerkinElmer. He has also held technical sales and marketing positions at BectonDickinson and BeckmanCoulter. Mr. Rodewald received his AB Chemistry/Biology from Indiana University and an MBA from Georgia State University.
Dr. Menard Rose has over 20 years of experience in Cell Line and Process Development. She obtained her Ph.D in Biological and Medical Engineering from the University of Paris XIII, where she worked with Pasteur Merieux and Rhone-Poulenc. She has held postdoctoral positions at the University of California, San Francisco and the University of Utah where she was awarded several grants for her work. Prior to joining Aragen, she was at Coherus Biosciences as Associate Director, Cell Process Development and Glycobiology where she directed Cell Line Development on several early stage biosimilar pipeline candidates. Before this she has held scientific positions at Aragen Bioscience, Celliance Corporation, Sierra Biosource, University of California, San Francisco and Pasteur Merieux . She led several groups responsible for the development of Biologics specialized in “Difficult to Express” molecules and upstream processes required for the optimization of the quality attributes of very broad types of Biologics. Dr. Menard Rose recently rejoined Aragen Bioscience in 2016 and is Director of Cell Line Development and Upstream Process Development.
Dr. Myles is an experienced protein biochemist with over 20 years experience in academia and biotech/pharma. He obtained his Ph.D in Biochemistry and Biophysics from the University of Cambridge and has held postdoctoral positions at Novartis (FMI) and Stanford University. He has worked as a senior scientist at Stanford University, Genesis Research and Development Corporation, Maxygen Inc, and Perseid Therapeutics encompassing protein biochemistry, enzymology/binding kinetics and assay development. He recently left Bayer Healthcare where he was a project leader responsible for three translational research and development programs for procoagulant therapy (hemophilia & acute bleeding) and hemoglobinopathies (sickle cell anaemia & beta-thalassemia), managed as in vitro assay group and was the global project team preclinical research lead for BayVII. Dr. Myles has extensive theoretical and technical expertise in molecular biology, protein biochemistry, assay development and PD/biomarker assay development. He has published extensively and an invited speaker for several international symposia.